• Cosmos Health entered a five-year distribution and promotion partnership with Libytec to commercialize its DIABIT-IS X diabetes drug in Greece.
• Cosmos will supply DIABIT-IS X (sitagliptin); Libytec will manage distribution, medical information, and promotion across physicians, pharmacies, and hospitals.
• DIABIT-IS X is a generic alternative to Merck’s Januvia; Januvia and Janumet generated about $4.5 billion in global sales in 2022.
• The product is expected to be accessible via Greece’s national health insurance system, supporting broader patient reach.
• The agreement is expected to improve revenue and cash-flow visibility, supporting expansion into additional European markets over time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607131300OMX_____CNEWS_EN_GNW9761225_en) on July 13, 2026, and is solely responsible for the information contained therein.